IS THERE ANY POINT INCARDIOMETABOLIC THERAPY IN THE TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE AND TYPE 2 DIABETES MELLITUS? (literature review)

Authors

  • Zhuravlyova L. V. Kharkiv National Medical University, Kharkiv
  • Lopina N. A. Kharkiv National Medical University, Kharkiv

DOI:

https://doi.org/10.21856/j-PEP.2016.4.13

Keywords:

coronary artery disease, metabolic therapy, mexicor

Abstract

The article focused on coronary artery disease, as it takes a leading place in the structure of cardiovascular morbidity and mortality. The article described pathogenetic mechanisms of influence the ischemia on the myocardium, particularly of energy production in the myocardium in norm and ischemia. The basic therapeutic strategies to reducing ischemia were described. Discussed reasons for the persistence of pain in the heart after «successful» revascularization. Substantiated along with the standard therapy the use of cardiometabolic medications in cytoprotection ischemia. The article described the classification cytoprotectors on the specifics of the pharmacological effect. Substantiated clinical application of Mexicor.

References

Biduchak AS, Shkrobanec’ ID, Leonec’ SI. Bukovyns’kyj Med Visn 2013; 17(3):100-103.

Stabil’na ishemichna hvoroba sercja: adaptovana klinichna nastanova, zasnovana na dokazah, Kyi’v, 2016: 177 p.

Hakaz MOZ Ukrai’ny vid 02.03.2016; 152:61 p.

Rekomendacii po diabetu, prediabetu i serdechnososudistym zabolevanijam. EASD/ESC. Ros Kardiol Zhurn 2014; 107(3):6-70.

Malberg K, et al. Circulation 2000; 102:1014-1019. doi: http://dx.doi.org/10.1161/01.CIR.102.9.1014

American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2016; 39(1):S.1-S.109.

Luca G, Gibsonb M, Bellandic F, et al. Atherosclerosis 2009; 207:181-185. doi: http://dx.doi.org/10.1016/j.atherosclerosis.2009.03.042

Luca G, Dirksen MT, Spaulding C, et al. Diabetes Care 2013; 36:1020-1025. doi: http://dx.doi.org/10.2337/dc12-1507

Parhomenko AN, Kozhuhov SN. Mezhdunar Med Zhurn 2004; 2:6-11.

Parhomenko AN, Bryl’ ZhV. Ukr Kardiol Zhurn 2000; 5-6:95-99.

Dolzhenko MN. Mystectvo Likuvannja 2012; 2-3(88-89):1-8.

Lutaj MI, Golikova IP. Zdorov’e Ukrainy 2010; 3:16-18.

William E, et al. N Engl J Med 2007; 356(15):1503-1516. doi: http://dx.doi.org/10.1056/NEJMoa070829

Montalescot G, Sechtem U, Achenbach S, et al. Eur Heart J 2013; 34:2949-3003. doi: http://dx.doi.org/10.1093/eurheartj/eht296

Simoons ML, Windecker S. J Am Coll Cardiol 2010; 3(7):695-704. doi: http://dx.doi.org/10.1016/j.jcin.2010.05.004

Parhomenko AN. Ukr Kardiol Zhurn 2010; 1:9-16.

Jaffe R, Dick A, Strauss BH, et al. J Am Coll Cardiol 2009; 2(1):85-86. doi: http://dx.doi.org/10.1016/j.jcmg.2008.11.003

Jespersen L, Abildstrom SZ, Hvelplund A, et al. Eur Heart J 2013; 34:3294-3303. doi: http://dx.doi.org/10.1093/eurheartj/eht309.P3294

Windecker S, Kolh P, Alfonso F, et al. Eur Heart J 2014. doi: http://dx.doi.org/10.1093/eurheartj/ehu2

Marzilli M, Merz CN, Boden WE, et al. J Am Coll Cardiol 2012; 60:951-956. doi: http://dx.doi.org/10.1016/j.jacc.2012.02.082

Fang YZ, Yang S, Wu GY. Nutrition 2002; 18(10):872-879. doi: http://dx.doi.org/10.1016/S0899-90070200916-4

Ferrari R, Ceconi C, Curello S, et al. Am J Med 1991; 91:S95-S105. doi: http://dx.doi.org/10.1016/0002-9343(91)90211-F

Marzilli M, Huqi A. Heart Metabol 2010; 46:35-37.

Ndrepepa G. J Am Coll Cardiol 2010; 55(21):2383-2389. doi: http://dx.doi.org/10.1016/j.jacc.2009.12.054

Gaal WJ, Banning AP. Expert Rev Cardiovasc Ther 2007; 5(4):715-731. doi: http://dx.doi.org/10.1586/14779072.5.4.715

Rezkalla SH, Kloner RA. Catheter Cardiovasc Interv 2008; 72(7):950-957. doi: http://dx.doi.org/10.1002/ccd.21715

Valero SJ, Moreno R, Reyes RM, et al. Cardiovasc Hematol Agents Med Chem2008; 6(2):125-129. doi: http://dx.doi.org/10.2174/187152508783955079

Iwakura K, Ito H, Ikushima M, Kawano S, et al. J Am Coll Cardiol 2003; 1:1-7. doi: http://dx.doi.org/10.1016/S0735-1097(02)02626-8

Tartan Z, Ozer N, Uyarel H, et al. NutrMetab Cardiovasc Dis 2008; 18(6):441-447. doi: http://dx.doi.org/10.1016/j.numecd.2007.02.015

Astashkin EI. Serdce i Metabolizm 2008; 21:1-3.

Bobrov VA, Davydova IV, Makarevskij AI. Novosti Mediciny i Farmacii. Kardiologija2010; 327.

Mihin VP, Savel’eva VV, Grigor’eva TV. Med Akad Zhurn 2006:1-7.

Golikov AL, Polumiskov VJu, Mihin VL, et al. Kardiovaskuljarnaja Terapija i Profilaktika 2004; 6:66-74.

Golikov AP, Polumiskov VJu, Bojcov SA. CJeMPINFORM 2002; 6(54):14-23.

Golikov AP, Polumiskov VJu, Mihin VP, et al. Agrokurort 2005; 2:13-20.

Golikov AP, Mihin VP, Polumiskov VJu, et al. Terapevt Arh 2004; 4:60-65.

Alimenko JuN, Sidorova NV, Dmitrochenko LD. Bull Med Internet Conf 2015; 5(5):532-534.

Stacenko ME, Turkina SV, Kosivcova MA. Klin Medicina 2013; 5:59-64.

Golikov AP, Luk’janov MM, Polumiskov VJu, et al. Kardiovaskuljarnaja Terapija i Profilaktika 2005; 3:10-16.

Klebanova EM, Balabolkin MI, Kreminskaja VM, et al. Terapevt Arh 2006; 8:67-70.

Shljahto EV, Treshkur TV, Parmon EV, et al. Vestn Aritmologii2006; 44:5-11.

Shljahto EV, Galagudza MM, Nifontov EM. Serdechnaja Nedostatochnost’ 2005; 4:148-155.

Stacenko ME, Turkina SV, Evtereva ED. Ros Kardiol Zhurn 2009; 80(6):49-55.

Shevchuk VE, Bruev AN, Kacaj VV, Kostjukovich TI. Mitohondrial’nye Citoprotektory: Segodnjashnij Den’ i NovyePperspektivy 2009; 6:122-124.

Stacenko ME, Turkina SV. Arh Vnutr Mediciny 2013; 11(3): 63-69.

Downloads

Published

2021-06-24

How to Cite

Zhuravlyova, L. V., & Lopina, N. A. (2021). IS THERE ANY POINT INCARDIOMETABOLIC THERAPY IN THE TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE AND TYPE 2 DIABETES MELLITUS? (literature review) . Problems of Endocrine Pathology, 58(4), 105-120. https://doi.org/10.21856/j-PEP.2016.4.13